Olea pollen allergy immunotherapy - ALK-Abello

Drug Profile

Olea pollen allergy immunotherapy - ALK-Abello

Alternative Names: AVANZ olea; AVANZ Olive; AVANZ Olivo; Immunotherapy Olea europaea

Latest Information Update: 15 Dec 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator ALK-Abello
  • Class Allergens; Antiallergics; Tree pollen allergy immunotherapies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Allergic rhinoconjunctivitis

Most Recent Events

  • 25 Nov 2016 Launched for Allergic rhinoconjunctivitis in Spain before November 2016 (SC) (ALK-Abello email communication)
  • 01 Sep 2012 Phase-II/III clinical trials in Allergic rhinoconjunctivitis in Spain (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top